• Fri May 31 2024

    Pluvia Receives European Orphan Drug Designation

    Pluvia newly announced that the European Medicines Agency (EMA) Committee for Or

    Read full article
  • Tue Apr 30 2024

    Sarsia invests in maritime green-tech company Cetasol

    Sarsia participates in a €2M seed round in Cetasol (, a technolo

    Read full article
  • Fri Feb 16 2024

    Sarsia is proud sponsor of WILD - Women in Life Science Norway

    Sarsia Management is proud to announce that we are among the first sponsors of t

    Read full article
  • The Arxx Team: Berte Poulsson– VP Quality Assurance and Regulatory,  Sylvia Vetrhus– VP Clinical Research and Jonas Hallén – Chief Medical Officer

    Wed Jan 24 2024

    Arxx merges with Oxitope and raises EUR 75 million in a Series A

    Arxx Therapeutics and Oxitope Pharma today announced their merger to form Callu

    Read full article
  • Wed Oct 04 2023

    Pluvia Biotech appoints Willem van Weperen as new CEO

    Pluvia Biotech announces the appointment of Willem van Weperen as its new Chief

    Read full article
  • Thu Sep 14 2023

    Meet us at LSX Nordic and BioFIT this fall

    Sarsia Partner Farzad Abdi-Dezfuli will participate in two high-level biotech pa

    Read full article
  • Mon May 08 2023

    Henrik Solberg-Johansen joins the Sarsia team

    Henrik Solberg-Johansen joined the Sarsia team on May 1st.

    Read full article
  • Mon May 08 2023

    Arxx Therapeutics initiates first-in-human trial

    Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases

    Read full article
  • Wed Apr 26 2023

    Sveinung Hole to become new CEO in Sarsia

    Sarsia Management AS announced today that Sveinung Hole has been appointed as Ma

    Read full article
  • Tue Mar 07 2023

    OculAudio signs deal with hearing implant giant

    OculAudio ® Corti AS today announced that it has entered of a collaborative rese

    Read full article
  • Mon Jan 02 2023

    Coegin Pharma raises 25 mSEK

    Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new issue

    Read full article
  • Fri Dec 16 2022

    Rallybio publishes promising results with technology aquired from Prophylix Pharma

    American biotech company Rallybio publishes proof-of-concept data from animal studies with technology aquired from Tromsø-based Prophylix Pharma

    Read full article

Read more about our work

  • Approach

    Reliability is at the core of what we do

    Visit page
  • Life Sciences

    We invest in a healthier future

    Visit page
  • Technology, Energy and Sustainability

    We are conscious of our responsibility

    Visit page